Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で113.93%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 2.29Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 2.29Mです。
割安
同社の最新のPEは-1.59で、過去3年間の水準と比較して安値圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は6.18M株で、前四半期比で16.17%増加しています。
バンガードが保有
スター投資家バンガードは本銘柄を0.00株保有しています。